PO.CH01.07 · 化学

MTA-DTA:一个用于药物-靶标结合亲和力预测的多token注意力框架

MTA-DTA: A multi-token attention framework for drug-target binding affinity prediction

海报缩略图:MTA-DTA:一个用于药物-靶标结合亲和力预测的多token注意力框架
编号 981 展板 8 时间 4/19 02:00–05:00 区域 Section 38 主讲 ilsan Jeong, MS
分会场 Computational, Technological, and Mechanistic Advances
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Il-san Jeong, Seung-Woo Baek, Jee-Woo Seo, Yeo-Gyeong Yoon, Jae-Yoon Kim, Seon-Young Kim, Seon-Kyu Kim

Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon-city, Korea, Republic of

摘要 Abstract

中文摘要
背景:准确预测药物-靶标亲和力(DTA)是药物发现中的关键步骤,但实验测量仍然成本高昂且耗时。基于深度学习的方法近来使用药物和蛋白的序列级或图级表征展现出强劲的性能,而注意力机制通过突出关键的分子子序列提供了可解释性。然而,传统注意力计算单个token对之间的依赖关系,无法完全捕获表征真实蛋白-配体相互作用的协同性和多残基结合行为。 方法:我们提出一种基于多token注意力(Multi-Token Attention,MTA)的DTA模型,对药物与靶蛋白之间的全局和局部相互作用上下文进行建模。该模型在广泛使用的Davis和KIBA基准数据集上进行训练与评估以预测结合亲和力。蛋白序列和药物SMILES均使用预训练模型进行嵌入——蛋白使用ESM2(esm2_t33_650M_UR50D),化合物使用ChemBERTA(ChemBERTAa-77M-MTR)。MTA模块在注意力计算之前引入按键(key-wise)卷积以聚合局部token邻域,并引入头部混合(head-mixing)卷积以融合跨头信息,从而实现多token的上下文依赖。 结果:在两个基准数据集上,MTA-DTA持续优于先前的方法。在Davis上,它实现了0.225的MSE、0.7155的R²和0.8796的CI。在KIBA上,它达到0.1612的MSE、0.7661的R²和0.8781的CI,超越了现有DTA模型的性能。此外,对注意力图的定性分析表明,MTA捕获了具有生物学意义的结合区域,突出的是连续的残基片段和亚结构基序,而非孤立的token对。这表明该模型有效整合了局部化学上下文和全局相互作用模式,从而在药物-靶标亲和力预测中提升了准确性和可解释性。 结论:总之,MTA-DTA模型通过将注意力从单token扩展到多token相互作用建模,增强了传统注意力,从而弥合了基于序列的学习与分子结合真正的协同本质之间的鸿沟。通过引入按键卷积和头部混合卷积,该模型获得了表征局部相互作用基序的能力,同时保持对全局依赖的感知,从而产生更符合生物学实际的亲和力预测。
查看英文原文 English abstract
Backgrounds: Accurate prediction of drug-target affinity (DTA) is a key step in drug discovery, but experimental measurement remains costly and time-consuming. Deep learning-based approaches have recently shown strong performance using sequence- or graph-level representations of drugs and proteins, and attention mechanisms provide interpretability by highlighting key molecular subsequences. However, conventional attention computes dependencies between single token pairs, which cannot fully capture the cooperative and multi-residue binding behaviors that characterize real protein-ligand interactions. Methods: We propose a Multi-Token Attention (MTA)-based DTA model that models both global and local interaction contexts between drug and target proteins. The model was trained and evaluated on the widely used Davis and KIBA benchmark datasets for binding affinity prediction. Protein sequences and drug SMILES were both embedded using pretrained models - ESM2 (esm2_t33_650M_UR50D) for proteins and ChemBERTA (ChemBERTAa-77M-MTR) for compounds. The MTA module incorporates key-wise convolution to aggregate local token neighborhoods before attention calculation and head-mixing convolution to fuse inter head information, allowing multi-token contextual dependencies. Results: Across two benchmark datasets, MTA-DTA consistently outperformed prior methods. On Davis, it achieved an MSE of 0.225, R² of 0.7155, and CI of 0.8796. On KIBA, it reached an MSE of 0.1612, R² of 0.7661, and CI of 0.8781, exceeding the performance of existing DTA models. In addition, qualitative analyses of the attention maps revealed that MTA captured biologically meaningful binding regions, highlighting continuous residue segments and sub-structural motifs rather than isolated token pairs. This indicates that the model effectively integrates both local chemical context and global interaction patterns, leading to improved accuracy and interpretability in drug-target affinity prediction. Conclusion: In summary, the MTA-DTA model enhances conventional attention by extending it from single-token to multi-token interaction modeling, thereby bridging the gap between sequence-based learning and the true cooperative nature of molecular binding. By incorporating key-wise and head-mixing convolutions, the model gains the ability to represent local interaction motifs while maintaining global dependency awareness, resulting in more biologically realistic affinity predictions.
利益披露 Disclosure
I. Jeong, None.. S. Baek, None.. J. Seo, None.. Y. Yoon, None.. J. Kim, None.. S. Kim, None.. S. Kim, None.

← 返回 AACR 2026 检索